Rob Ottenstein

Schulten attributed the gap to P&G's scale and velocity rather than strategy; Jejurikar could not isolate a gasoline effect but flagged a top-line multiplier if the Middle East conflict sustains.

Andre confirmed restructuring is on track across all components: portfolio exits slightly ahead, headcount reduction in line with trajectory, and technology/automation rollouts progressing.

Andre quantified the Q4-to-Q3 pull forward at about 1 point, meaning underlying organic growth would have rounded to 3% rather than a strong 3%. Kept the explanation simple.

Andre said strongest core plus premium bigger-more innovation drives online; Shailesh cited India e-commerce growing 10x offline as an example of channel focus.

Andre pushed back on affordability framing; cited premium trade-up, private label declining below 16%, and pack/channel strategies for stretched consumers.

Jon described pack size strategy, innovation-led cost reduction and pricing ladder fill; pushed back on superiority-equals-premium misperception.

Andre said pricing is innovation-led; deflected on retailer private-label strategy commentary.

Jon declined to quantify innovation but cited confidence from Tide Evo results and whole body deodorant growth.

Andre detailed channel, media and benefit shifts and rebuilt distributor partnerships; said SK-II's 'brown shoots' are disappearing, not yet green.

Noel detailed China execution: mid-single-digit Colgate China growth, low-single-digit Darlie growth, and exporting Chinese digital innovation and talent.

Noel detailed strong Hill's performance: U.S. up 5%, Prescription Diet double-digit growth, share gains across channels. Private label drag of 260 basis points tapering. Dry dog only weak segment.

Wallace described active transfer of China omni-demand learnings globally. H&H replicating Colgate China's e-commerce strategy with successful super-premium dual chamber technology launch. Structural changes underway.

Wallace said Total got out of gates strong with incremental share gains. Reformulated product rolling in with shares recovering. Drugstore channel challenged but reengaging with retailers on mid-store traffic.

Wallace reported strong incremental share from Total relaunch across 75 markets. LatAm seeing consumer cautiousness with Mexico improving slightly but Brazil decelerating. Pricing flowing through in H2.

Wallace cited strong market share gains in oral care on both Colgate and Elmex. Elmex expanding selectively into Brazil and Middle East as a 5-10 year strategy, not short-term.

Wallace reported terrific share growth from LatAm Total launch. Rolling to Asia, North America, Europe. Meaningful formula upgrade focused on prevention across toothpaste, toothbrush, mouthwash.

Explained the customer-centric shift and portfolio approach but gave no volume sizing or transition timing.

Henrique framed APAC as long-term investment play, highlighted disciplined category selection in China and local brand portfolio in India, acknowledged margin work remains.

John explained hedging enables consistent local investment while growing USD earnings. Well-hedged on G10 currencies. EM hedging limited by economics. 1% NSR tailwind and 3% net income tailwind for 2026.

James confirmed GLP-1 data showing shift away from full sugar toward diet, hydration, coffee and protein. New York capacity on track to ramp through 2026.

James called global consumer resilient overall. ASEAN was the most surprising area of weakness. Events coming in and out at faster velocity than historically.

James clarified growth moderation is percentage-based, not dollar-based. Major capacity coming online year-end. Will enable unconstrained growth and expanded innovation.

James framed new brands and shelf space as positive for industry but didn't address KO's specific plans. Pivoted to track record of scaling brands.

Laguarta said beer partnerships like Carlsberg add on-premise presence and in-home execution scale where PepsiCo is not the leader, citing share gains in the U.K.

Laguarta said physical integration of warehouses and transport is working, applies to some regions only, with details deferred to a future investor meeting.

Laguarta stressed international is not being starved of capital; U.S. productivity (automation, digitalization, combined U.S. logistics and mixing centers in Texoma) funds the U.S. transformation with positive returns.

Steve cited cases per hour, headcount reductions, plant closures, SKU rationalization. Ramon added global shared services, AI in supply chain and transportation, digital ordering, and Texas supply chain integration tests.

Ramon described guidance as continuistic from Q4; Mexico improving, China positive, Middle East strong, Western Europe weaker, Brazil neutral. No macro improvement assumed.

Ramon described dual urgency on portfolio and cost transformation; technology investment over five years now enabling AI and automation. On CFO, thanked Jamie for 33 years; Steve brings right experience, skills, and culture fit for strategy 2030 execution.

Ramon highlighted three international beverage platforms: no-sugar colas, energy (Sting), and hydration (Gatorade). On refranchising, framed NA integration as prioritizing cost reduction and growth opportunities over the next 3-4 years.

Fink gave mid-teens first-half Victoria growth and described its distinct authentic-Mexican positioning, but gave no market-share figure or size target.

Fink pointed to in-field execution, distribution gaps and pack-price architecture, but declined to be overly telegraphic on competitive ideas.

Bill highlighted $900M+ returned to shareholders in FY26 despite challenging environment. Garth noted FY26 CapEx came in significantly below starting expectations, will continue managing modularly. No guidance beyond FY27 but expects cyclical headwinds to ease.

Bill detailed Pacifico as #2 in California, skews younger, #1 social media share of voice, gained 1.5 points in on-premise. Following Modelo's west-to-east expansion playbook.

Bill reframed Corona as a brand family, Familiar is a top share gainer, Sunbrew is #1 new brand in dollars and #4 overall share gainer. Corona Extra's brand health metrics measured by intent to buy and first choice remain strong.

Garth outlined $9B operating cash flow and $6B FCF through FY28, committed to 3x leverage and 30% dividend payout. M&A remains last priority, focused on smaller plug-in opportunities.

Bill noted slightly higher border-side inventory as tariff precaution, expects continued shelf gains in coming year though likely more normalized than double-digit prior year.

Rahul said Monaco is tracking slightly ahead of expectations on both top and bottom line, concentrated in about 5 states and convenience singles. Priority is preserving execution (80+ retained staff), then expanding channels and states in a measured, disciplined way.

Rahul said short/medium-term goal is stabilizing Miller Lite share, with Great Lakes area the primary challenge requiring targeted regional action. Feels good about current campaign and plans including Americas 250th activation leveraging taste and Americana angles. Believes regional execution rather than fundamental brand refresh is the current path forward.

Rahul explained leadership changes brought sales, marketing, and Canadian leaders to the table. Regions reoriented in the U.S. with investments viewed as a collective pool optimized by geography for ROI. Brands show up one way nationally but executed differently by market. Distributor planning conversations already changed. Incentive plans redesigned with P&L accountability closest to market.

Rahul stated emphatically no constraints or sacred cows from the Board. Mandate is maximizing shareholder value. Acknowledged category challenges but pointed to great geographies with big profit pools. Will deploy balance sheet for portfolio augmentation while returning cash to shareholders.

Gavin said shelf gains held with no significant fall 2025 activity expected in traditional beer space. Noted removing Pabst freed capacity for Peroni onshoring and Yuengling partnership expansion. Industry comps actually get tougher after July as industry improved from August onward last year.

Gavin declined specific Fever-Tree financial projections but noted integration costs in the tens of millions. On tariffs, emphasized domestic production and sourcing. Tracey clarified 100% U.S. revenue recognition with EBITDA-level profit sharing.